Holen Sie sich die Stockscreener-App
20.25
0.20%
-0.04
Schlusskurs vom Vortag:
$20.29
Offen:
$20.43
24-Stunden-Volumen:
44,471
Relative Volume:
0.96
Marktkapitalisierung:
$77.53M
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
-1.22%
1M Leistung:
-0.34%
6M Leistung:
-11.96%
1J Leistung:
-26.71%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$19.52
$21.16
52-Wochen-Spanne:
$18.19
$37.50
Pelthos Therapeutics Inc. Stock (PTHS) Company Profile
Firmenname
Pelthos Therapeutics Inc.
Sektor
Branche
Telefon
-
Adresse
-
Compare PTHS vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTHS
Pelthos Therapeutics Inc.
|
20.25 | 77.53M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pelthos Therapeutics Inc. Stock (PTHS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-27 | Eingeleitet | Piper Sandler | Overweight |
| 2025-12-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-12-03 | Eingeleitet | Lake Street | Buy |
| 2025-11-25 | Eingeleitet | Roth Capital | Buy |
| 2025-09-02 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Pelthos Therapeutics Inc. Aktie (PTHS) Neueste Nachrichten
Pelthos Therapeutics (PTHS) Stock Fair Value Falls After Analysts Cut Zelsuvmi Launch Estimates - Yahoo Finance
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock Rating Lowered by Zacks Research - MarketBeat
Pelthos Therapeutics director Matthew Pauls sells $16,506 in shares By Investing.com - Investing.com Australia
Pelthos Therapeutics director sells $11,560 in common stock By Investing.com - Investing.com Nigeria
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells 558 Shares of Stock - MarketBeat
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock: Insider Peter Greenleaf Sells 797 Shares - MarketBeat
Pelthos Therapeutics director Peter Greenleaf sells $16,872 in stock By Investing.com - Investing.com Nigeria
Pelthos Therapeutics director sells $11,560 in common stock - Investing.com
Pelthos Therapeutics director Peter Greenleaf sells $16,872 in stock - Investing.com
Pelthos Therapeutics director Matthew Pauls sells $16,506 in shares - Investing.com
Form 4 Pelthos Therapeutics Inc For: 6 October By Investing.com - Investing.com India
Form 4 Pelthos Therapeutics Inc For: 6 October By Investing.com - Investing.com UK
Under a trading plan, Pelthos Therapeutics (PTHS) director sells 797 shares at $21.17. - Stock Titan
For estimated vesting taxes, a Pelthos Therapeutics (PTHS) director sold 786 shares at $21. - Stock Titan
Pelthos expands ZELSUVMI coverage to 127 million lives - Investing.com
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% - The Manila Times
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% - GlobeNewswire
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% - GlobeNewswire
PTHS PE Ratio & Valuation, Is PTHS Overvalued - Intellectia AI
Form 8K Pelthos Therapeutics Inc For: 1 October By Investing.com - Investing.com Australia
Form 8K Pelthos Therapeutics Inc For: 1 October By Investing.com - Investing.com Nigeria
Pelthos Therapeutics elects directors and approves new equity plan at annual meeting - Investing.com
Pelthos Shareholders Approve 2026 Equity Plan With 500,000-Share Reserve - Minichart
Form 8K Pelthos Therapeutics Inc For: 1 October By Investing.com - Investing.com UK
Stockholders elect eight directors as Pelthos Therapeutics (PTHS) adopts its 2026 stock incentive plan. - Stock Titan
Pelthos Therapeutics Inc (PTHS-A) Stock Price and News - The Globe and Mail
Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings: Deep EPS Miss Sends Shares LowerRevenue Warning Signal - careplusvn.com
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings: Deep EPS Miss Sends Shares LowerQuarterly Earnings - dars.gov.et
Pelthos Therapeutics Inc. SEC Filing (Aug 18, 2026) - Stock Titan
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewswire
Pelthos Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings call transcript: Pelthos Therapeutics posts Q2 2026 revenue growth, but EPS miss weighs - Investing.com
Pelthos Therapeutics Inc. 2026: Revenue $15.6M, Net income ($23.42M), EPS ($6.62) — 10-Q Summary - TradingView
Earnings To Watch: Pelthos Therapeutics Inc (PTHS) Reports Q2 2026 Result - Yahoo Finance
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026 - GlobeNewswire
Pelthos Therapeutics (PTHS) Surges 9.18% to $28.66: Key Levels to WatchIsland Reversal - careplusvn.com
Pelthos Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Drives 9.18% Stock JumpNegative Surprise Momentum - careplusvn.com
PTHS Q1 2026 Earnings: Smaller-than-Expected Loss Drives Modest Stock GainWeak Earnings Momentum - careplusvn.com
Pelthos Therapeutics Added to Russell 3000E™ Growth - GlobeNewswire
PTHS Forecast — Price Target — Prediction for 2027 - TradingView
Pelthos Therapeutics stock rises on director share purchase - Investing.com
Why is Pelthos Therapeutics stock rallying today? - Investing.com
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - Yahoo Finance
Pelthos Therapeutics Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Pelthos Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Pelthos Therapeutics Announces First Quarter 2026 Financial Results - GlobeNewswire
Pelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain - Yahoo Finance
Finanzdaten der Pelthos Therapeutics Inc.-Aktie (PTHS)
Es liegen keine Finanzdaten für Pelthos Therapeutics Inc. (PTHS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Pelthos Therapeutics Inc.-Aktie (PTHS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pauls Matthew | Director |
Oct 02 '26 |
Sale |
21.00 |
786 |
16,506 |
13,578 |
| Friedberg Ezra M | Director |
Oct 02 '26 |
Sale |
20.72 |
558 |
11,560 |
80,484 |
| Pauls Matthew | Director |
Jul 02 '26 |
Sale |
26.16 |
786 |
20,561 |
14,364 |
| Greenleaf Peter | Director |
Jul 02 '26 |
Sale |
26.13 |
797 |
20,827 |
23,884 |
| Friedberg Ezra M | Director |
Jul 02 '26 |
Sale |
26.09 |
558 |
14,556 |
81,042 |
| Friedberg Ezra M | Director |
Jun 15 '26 |
Sale |
27.29 |
283 |
7,724 |
81,600 |
| Davis Todd C | Director |
Jun 11 '26 |
Buy |
27.82 |
35,948 |
999,983 |
75,834 |
| Francis Knuettel II | Officer |
May 22 '26 |
Proposed Sale |
27.11 |
1,720 |
46,629 |
0 |
| Francis Knuettel II | CFO, Treas & Secty |
May 22 '26 |
Sale |
26.84 |
1,500 |
40,265 |
11,316 |
| Greenleaf Peter | Director |
Apr 02 '26 |
Sale |
20.92 |
797 |
16,670 |
24,681 |
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):